Patent Application
20110104126
The present invention relates to a human hepatic stem cell, a method of preparing the same, a method of inducing differentiation of the same, and a method of using the same.
Conventionally, isolation of stem cells has been performed by centrifugation (Non-Patent Document No. 1). However, this method is prone to contamination of stem cells by non-stem cells. Thus, efficient isolation has been difficult. Under the circumstances, development of a method capable of isolating stem cells alone at higher efficiency has been pursued. According to recent reports, it is believed that isolation methods using monoclonal antibodies to cell surface antigens specific for the stem cells of individual organs are most appropriate, and such methods are frequently used for isolation of hematopoietic stem cells. Although cell surface antigens specific for hepatic stem cells have not been identified yet, the group of the present inventors has reported a method of concentrating hepatic stem cells from mouse livers using the expression of 5 to 6 cell surface antigens as indicators (Non-Patent Documents Nos. 2 and 3). Miyajima et al. have reported that dlk (delta-like) and Itm2A (Integral membrane protein 2A) genes are highly expressed specifically in hepatic stem cells of mouse fetal and adult livers, and that it is possible to detect or isolate hepatic stein cells using the expression of these proteins or mRNAs as indicators (Patent Document No. 1). Further, it has been also reported that isolation of rat hepatic stem cells based on the expression of specific sugar chains is possible (Patent Document No. 2).
Further, it has been reported that p75NTR which was believed to be a marker protein for stem cells in ectodermal tissues is synthesized in all kinds of tissue, and the combination of this marker with a known marker protein improves the efficiency of isolation, identification and differentiation induction of pluripotent stem cells (Patent Document No. 3).
Identification and analysis of molecular markers which recognize hepatic stem cells have progressed, and methods of isolation/culture thereof have been reported. However, such reports made to date are about rat or mouse hepatic stem cells; no reports have been made about human hepatic stem cells. The present inventors have actually confirmed that it is impossible to isolate human hepatic stem cells using conventional hepatic stem cell markers reported on mouse and rat. Thus, it has been necessary to establish an isolation method with the molecular markers specific for human hepatic stem cells.
Since drug metabolizing ability differs greatly between human liver cells and experimental animals' liver cells, it is difficult to predict the drug metabolizing ability in human liver cells from those results obtained by using experimental animals or liver cells isolated therefrom. Therefore, establishment of a technology to isolate human hepatic stem cells specifically and to differentiate/proliferate the resultant cells into human liver cells in a culture system has been demanded.
Moreover, a large number of reports made so far describe isolation methods for hepatic stem cells using a single marker. While such methods are capable of saving time and labor, they have a drawback of lacking the accuracy required for isolating only a small number of hepatic stem cells from a heterogeneous cell population.
It is an object of the present invention to provide a human hepatic stem cell.
It is another object of the present invention to provide a method of preparing the human hepatic stem cells, a method of inducing differentiation of the same, and a method of using the same.
In the present invention, a plurality of cell surface molecules expressed in human liver cell populations have been elucidated. Then, a method of isolating human hepatic stem cells using the expression of such molecules as indicators, a method of culturing the human hepatic stein cells and a method of using the human hepatic stem cells have been established. First, as a technique of isolating human hepatic stem cells, FACS (fluorescence activated cell sorting) more accurate than MACS (magnetic cell sorting) was used. Briefly, cells were fractionated using fluorescence-labeled monoclonal antibodies to a plurality of cell surface molecules and sorted by FACS. Then, using clonal colony-forming efficiency as an indicator, those cell fractions that contain highly proliferative human hepatic stem cells exclusively and at high frequency were screened. As a result, it was confirmed in human liver cells that cells with clonal colony-forming efficiency exist at high frequency and exclusively in cell fractions having the phenotypes of CD318+CD90+CD66−. Clonal colonies derived from a single CD318+CD90+CD66− cell expanded to 6×104 colonies or more in three weeks (doubling time: 31 hrs). Since it was found that a plurality of molecular markers (albumin, cytokeratin 8/18, cytokeratin 19, desmin, SMA and vimentin) specific for liver cells, cholangiocytes and hepatic stellate cells are expressed in those cells, it has become clear that CD318+CD90+CD66− cells have a pluripotency to differentiate into a plurality of different cell lineages constituting the liver.
Further, it was confirmed by semi-quantitative RT-PCR that CD318+CD90+CD66− cells isolated by FACS are strongly expressing a plurality of molecular markers (AFP, Bmi-1, Dlk, CD133 and vimentin) that are expressed in hepatic stem/progenitor cells or cancer stein cells. These results indicate that hepatic stem/progenitor cells having both high proliferative capacity and pluripotency exist exclusively and at high frequency in CD318+CD90+CD66− cell fractions in human fetal livers.
Further, the present inventors introduced the gene of BMI1 (one of the Polycomb group proteins which are known to be involved in replication competence that is characteristic of stein cells) into the isolated CD318+CD90+CD66− cells and established a human hepatic stein cell clone. Examination of the thus established clone revealed that the clonal colony-forming efficiency thereof is extremely high.
Further, in human liver cells derived from CD318+CD90+CD66− cells isolated by the above-described method, expression of a plurality of drug metabolizing enzymes (CYP3A4, 2D6, 2C9, 1A2, 2C19, 2A6, 2B6 and 2E1) and transporters (MRP2/3, MDR1 and BCRP) was confirmed by semi-quantitative PCR and an immuno-staining method. It was also confirmed that these genes are expressed similarly in human liver cells derived from a BMI1 gene-transfected human hepatic stem cell clone.
Further, it was detected by flow cytometry analysis that CD318+CD90+CD66− cells isolated by FACS were expressing CD81 tetraspanin (reported as a candidate for hepatitis C virus (HCV) receptor), scavenger receptor BI (SR-BI) and low-density lipoprotein (LDL). It was confirmed by DNA microarray analysis that the expression level of HCV receptor CD81 in FACS-sorted hepatic stem cells was significantly raised.
Further, expression of lipid metabolism-associated genes and glucogenesis-associated genes comparable to that found in human hepatic tissue was confirmed in three-dimensionally cultured transformed cells obtained by introducing BIM gene into the isolated CD318+CD90+CD66− cells. The expression levels of the lipid metabolism-associated genes and the glucogenesis-associated genes in the above-described three-dimensionally cultured transformed cells were confirmed to be close to their expression levels in human hepatic tissue.
Still further, the expression level of CD13 in FACS-isolated CD318+CD90+CD66− cells was raised, as compared to the expression level in primary fetal liver cells.
The present invention may be summarized as follows.
(1) A human hepatic stem cell sorted based on the presence or absence of the expression of at least one marker selected from the group consisting of CD318, CD90, CD66 and CD13.
(2) The human hepatic stem cell according to (1), which has the phenotype of CD31
(3) The human hepatic stem cell according to (1) or (2), which has the phenotype of CD90+.
(4) The human hepatic stem cell according to any one of (1) to (3), which has the phenotype of CD66−.
(5) The human hepatic stem cell according to (1), which has the phenotypes of CD318+CD90+CD66−.
(6) The human hepatic stem cell according to (5), which is a cell clone LSC-E2 deposited at the International Patent Organism Depository, National Institute of Advanced Industrial Science and Technology, Japan under accession number FERM BP-11108.
(7) The human hepatic stem cell according to any one of (1) to (6), which has the phenotype of CD13+.
(8) The human hepatic stem cell according to (1), which is a cell, or a progeny thereof, that has been obtained by proliferating into a cell population, a human hepatic stem cell clone sorted based on the presence or absence of the expression of at least one marker selected from the group consisting of CD318, CD90, CD66 and CD13 and then sorting cells from the cell population based on the presence or absence of the expression of at least one marker selected from the group consisting of CD318, CD90, CD66 and CD13.
(9) A transformed cell, wherein BMI1 gene has been introduced into the human hepatic stem cell according to (1).
(10) A method of preparing the human hepatic stem cell according to (1), which comprises sorting cells from a human liver cell population based on the presence or absence of the expression of at least one marker selected from the group consisting of CD318, CD90, CD66 and CD13.
(11) The method according to (10), wherein the human liver cell population is a primary liver cell culture line isolated from a human liver.
(12) The method according to (10), wherein after sorting cells from a human liver cell population based on the presence or absence of the expression of at least one marker selected from the group consisting of CD318, CD90, CD66 and CD13, the resultant cells are proliferated into a cell population and then cells are sorted again from this cell population based on the presence or absence of the expression of at least one marker selected from the group consisting of CD318, CD90, CD66 and CD13.
(13) The method according to (12), wherein cell sorting and proliferation are repeated twice or more.
(14) A method of preparing a liver cell which expresses drug-metabolizing enzymes and/or transporters at the protein level, the method of comprising inducing the differentiation of the human hepatic stein cell according to (1) and/or the transformed cell according to (9).
(15) The method according to (14), wherein the differentiation of the human hepatic stem cell according to (1) and/or the transformed cell according to (9) is induced by treatment with an extracellular matrix and/or a growth factor.
(16) The method according to (15), wherein the extracellular matrix and/or growth factor is at least member of the group consisting of laminin, type I collagen, type IV collagen, fibronectin, metrigel, dexamethasone, DMSO, oncostatin M, insulin, HGF, EGF, TGFα, HB-EGF, VEGF and PDGF.
(17) The method according to (14), wherein the differentiation of the human hepatic stem cell according to (1) and/or the transformed cell according to (9) is induced by three-dimensional culture.
(18) A liver cell expressing drug-metabolizing enzymes and/or transporters at the protein level, which has been prepared by the method according to (14)
(19) The liver cell according to (18), wherein the drug-metabolizing enzyme is at least one member of the group consisting of CYP3A4, CYP2C9, CYP2C19, CYP2D6, CYP2B6, CYP2E1 and CYP2A6.
(20) The liver cell according to (18), wherein the transporter is at least one member of the group consisting of ABC2, ABCA6, ABCA8, MDR1, MDR3, BSEP, MRP1, MRP2, MRP5, MRP6, ABCG8, NTCP, PEPT1, OATP-C, OATP8, OATP-B, OATP-F, OCT1, OAT2, SLC22A18, CNT1, ENT1, MATE1, MRP3 and BCRP.
(21) A method of evaluating the metabolism and/or transportation of a drug candidate compound using the liver cell according to (18).
(22) A bioreactor comprising the human hepatic stem cell according to (1), the transformed cell according to (9) and/or a liver cell which has been induced to differentiate therefrom.
(23) The bioreactor according to (22), which is used for as an artificial liver.
(24) A human model cell for experiments on HCV infection and/or inhibition of HCV replication, comprising the human hepatic stem cell according to (1), the transformed cell according to (9) and/or a liver cell which has been induced to differentiate therefrom.
(25) A human model cell for glucose metabolism experiments, comprising the human hepatic stein cell according to (1), the transformed cell according to (9) and/or a liver cell which has been induced to differentiate therefrom.
(26) A human model cell for lipid metabolism experiments, comprising the human hepatic stem cell according to (1), the transformed cell according to (9) and/or a liver cell which has been induced to differentiate therefrom.
(27) A method of using in regenerative medicine with the human hepatic stem cell according to (1), the transformed cell according to (9) and/or a liver cell which has been induced to differentiate therefrom.
(28) The method according to (27), wherein the regenerative medicine is cell therapy.
According to the present invention, it has become possible to isolate human hepatic stem cells more accurately because of the discovery of human hepatic stem cell markers as opposed to the conventional mouse or rat cell markers. The present inventors have actually confirmed that it is impossible to specifically detect human liver cells with conventional mouse hepatic stein cell markers. Thus, the significance of the present invention is great.
Further, since antigen-antibody reactions are used for cell isolation, the background level is smaller than in the methods using mRNAs or sugar chains as indicators. Thus, in the present invention, it is possible to isolate hepatic stem cells specifically as opposed to conventional methods.
For industrial application as in drug development, human liver cells retaining a maturing function are needed. It was confirmed that human liver cells induced to differentiate from human hepatic stem cells using the above-described technology were expressing various drug-metabolizing enzymes (CYPs) and transporters. Such human liver cells are highly valuable in performing screenings for drug development in such aspects as drug metabolism.
The present specification encompasses the contents disclosed in the specification and/or the drawings of Japanese Patent Application No. 2008-127755 based on which the present patent application claims priority.
Hereinbelow, the embodiment of the present invention will be described in detail.
The present invention provides a human hepatic stem cell sorted based on the presence or absence of the expression of at least one marker selected from the group consisting of CD318, CD90, CD66 and CD13. CD318 is an antigen molecule expressed in hematopoietic stem cells, mesenchymal stem cells, neural stem cells, etc. CD90 is an antigen molecule expressed in neural tissues, connective tissues, stromal cells, etc., and expression of this antigen molecule is also recognized in hematopoietic stem cells, mesenchymal cells and hepatic progenitor cells. CD66 has been reported as a granulocyte-specific antigen associated with carcinoembryonic antigen found in colon cancer cells and is an immunoglobulin super family molecule. CD13 is one of the mesenchymal stem cell markers. The human hepatic stem cell of the present invention may have at least one phenotype selected from CD318+, CD90+, CD66− and CD13+. The human hepatic stem cell of the present invention preferably has the phenotypes of CD318+CD90+CD66−, and more preferably the phenotypes of CD318+CD90+CD66−CD13+.
The human hepatic stem cell of the present invention is obtained by sorting cells of interest from a human liver cell population based on the presence or absence of the expression of at least one marker selected from the group consisting of CD318, CD90, CD66 and CD13. The present invention also provides a method of preparing a human tissue stem cell, which comprises sorting cells of interest based on the presence or absence of the expression of at least one marker selected from the group consisting of CD318, CD90, CD66 and CD13. The human liver cell population may be a population of any human liver cells. For example, a primary liver cell culture line isolated from a human liver (e.g., human fetal liver cells, Cat No. CS-ABI-3716, Cell Systems) may be given. After cells of interest are sorted from a human liver cell population based on the presence or absence of the expression of at least one marker selected from the group consisting of CD318, CD90, CD66 and CD13, the resultant cells are expanded into a cell population. From this cell population, cells of interest may be sorted again based on the presence or absence of the expression of at least one marker selected from the group consisting of CD318, CD90, CD66 and CD13 (
The human hepatic stem cell of the present invention has a high proliferative capacity and a potency to differentiate into liver cells and bile duct epithelial cells. The human hepatic stem cell of the present invention and cells which have been induced to differentiate therefrom are expected to be used as artificial livers or in regenerative medicine such as cell transplantation. With respect to the artificial liver, hybrid-type artificial livers consisting of a combination of liver cells and artificial devices are mainly used at present. As one example, an artificial liver bioreactor may be given which is prepared by attaching pig liver cells to fine beads approx. 2 mm in diameter and placing the resultant beads outside of the hollow fibers of a bioreactor composed of a bundle of hollow, semi-transparent membrane fibers (hollow fibers). This bioreactor has been clinically tested and achieved success to some extent. The human hepatic stem cell of the present invention and cells which have been induced to differentiate therefrom are applicable to bioreactors including artificial livers. Such bioreactors are not only used as artificial livers but also applicable to production of physiologically active substances such as human albumin and blood coagulation factors, assessment of the metabolism and transportation of drug candidate compounds, experiments on HCV infection and inhibition of HCV replication, experiments on glucose metabolism, experiments on lipid metabolism, and so forth. It is possible to create a bioreactor with a liver function by packing a matrix (such as artificial material) with the human hepatic stem cell of the present invention and cells which have been induced to differentiate therefrom.
It is possible to use the human hepatic stem cell of the present invention in regenerative medicine such as cell transplantation. Briefly, it is possible to perform orthotopic or heterotopic cell transplantation by injecting the human hepatic stem cell of the present invention into the spleen, the portal vein, the mesentery or the peritoneal cavity of immunosuppressant-administered patients with severe liver failure. Alternatively, it is possible to perform orthotopic or heterotopic cell transplantation by packing a matrix (such as artificial material) with the human hepatic stem cell of the present invention and cells which have been induced to differentiate therefrom and injecting the matrix into the spleen, the portal vein, the mesentery or the peritoneal cavity of patients with severe liver failure.
Further, since it was confirmed that those cells which have been induced to differentiate from the human hepatic stem cell of the present invention are expressing various drug-metabolizing enzymes (CYPs) and transporters, those cells may be used in screening for drug development (as in drug metabolism tests).
Further, since it was confirmed that the human hepatic stem cell of the present invention is expressing CD81 tetraspanin (reported as a candidate for HCV receptor), scavenger receptor BI (SR-BI) and low-density lipoprotein receptor (LDLR), the cell may be used as a human model cell for experiments of HCV infection and inhibition of HCV replication. Moreover, it was confirmed that the human hepatic stem cell of the present invention and cells which have been induced to differentiate therefrom are expressing lipid metabolism-associated genes and glucogenesis-associated genes. Therefore, those cells may be used as human model cells for lipid metabolism experiments and glucose metabolism experiments.
No culture system has yet been established for HCV-infected cells (excluding some HCV clones). Therefore, the mode of HCV infection has not bee elucidated yet. Except for chimpanzee, no HCV-sensitive experimental animals have been confirmed. Therefore, development of vaccines and therapeutics is extremely difficult. Briefly, the most important point in HCV researches is to develop a highly reproducible and efficient culture system. When establishment of a culture cell line of the hepatic stem cell of the present invention which is capable of highly expressing HCV binding receptors such as hCD81 and SR-BI becomes possible by three-dimensional culture system, then it becomes possible to perform HCV infection experiment, whereby the fusion between viral membrane and cellular membrane (which is most the important in viral infection) and the mechanism of invasion of the virus genome into cells can be investigated. Such a culture cell line is also applicable to drug development as in screening for blockers of new pathways of HCV infection routes. Further, it is also expected to use such a culture cell line in the development of therapeutic antibodies such as binding preventive antibodies against HCV receptors, virus-neutralizing antibodies and human type antibodies to HCV envelope proteins and in the activity assessment of human type antibodies.
Since it was confirmed that the human hepatic stem cell of the present invention and cells which have been induced to differentiate therefrom are expressing lipid metabolism-associated genes and glucogenesis-associated genes, these cells may be used as human model cells for lipid metabolism experiments and glucose metabolism experiments. With these cells, screening for various drugs associated with lipid metabolism and glucose metabolism may be performed. Briefly, it is possible to predict the effect of a drug which promotes or inhibits lipid metabolism or glucogenesis by adding the drug of interest into the culture broth.
The present invention also provides a transformed cell obtained by introducing BMI1 gene into a human hepatic stem cell sorted based on the presence or absence of the expression of at least one marker selected from the group consisting of CD318, CD90, CD66 and CD13. BMI1 is one of the Polycomb group proteins which are known to be involved in replication competence of cells and the genetic information thereof is registered at NCBI GenBank (GenBank accession number: NM—005180.5).
The transformed cell of the present invention may be prepared as described later in the Example. However, one of ordinary skill in the art could appropriately add alterations and modifications to the preparation method disclosed.
It has been found that introduction of BMI1 gene into the stem cell of the present invention enhances its clonogenicity. Further, it was confirmed that the genes of various drug-metabolizing enzymes (CYPs) and transporters expressed in those cells which have been induced to differentiate from the stem cell of the present invention are also expressed similarly in the BMI1-transfected human hepatic stem cell. In particular, it was confirmed that the expression level of CYP3A4 gene was raised compared to the level in the hepatic stem cell without BMI1-transfection. Therefore, it is believed that the BMI1-transfected human hepatic stem cell may also be used in drug development studies such as drug metabolism experiments. Further, it was confirmed that the lipid metabolism-associated genes and glucogenesis-associated genes expressed in those cells which have been induced to differentiate from the stem cell of the present invention are also expressed similarly in the BMI1-transfected human hepatic stein cell. The expression levels of such genes were confirmed to be close to their expression levels in human tissues. Therefore, it is believed that the BMI1-transfected human hepatic stem cell may also be used as human model cell for lipid metabolism experiments and glucose metabolism experiments. It has become possible to culture the BMI1-transfected human hepatic stem cell without using extracellular matrix-coated dishes which are essential for conventional liver cell culture systems. The BMI1-transfected human hepatic stem cell is also applicable to artificial livers, regenerative medicine such as cell transplantation, bioreactors, etc. and may also be used as a human model cell in experiments on HCV infection and inhibition of HCV replication.
Further, the present invention provides a method of preparing a liver cell which expresses drug-metabolizing enzymes and/or transporters at the protein level, the method comprises inducing the differentiation of a human hepatic stem cell sorted based on the presence or absence of the expression of at least one marker selected from the group consisting of CD318, CD90, CD66 and CD13 and/or a transformed cell wherein BMI1 gene has been introduced into the human hepatic stem cell. Specific examples of drug-metabolizing enzymes include, but are not limited to, CYP3A4, CYP2C9, CYP2C19, CYP2D6, CYP2B6, CYP2E1 and CYP2A6. Specific examples of transporters include, but are not limited to, MRP2, MRP3, MDR1 and BCRP. For example, one or two or more transporters selected from the following may be expressed: ABC2, ABCA6, ABCA8, MDR1, MDR3, BSEP, MRP1, MRP2, MRP5, MRP6, ABCG8, NTCP, PEPT1, OATP-C, OATP8, OATP-B, OATP-F, OCT1, OAT2, SLC22A18, CNT1, ENT1 and MATE1.
The differentiation into a liver cell which expresses drug-metabolizing enzymes and/or transporters at the protein level may be induced by treating with an extracellular matrix and/or a growth factor, when a human hepatic stem cell sorted based on the presence or absence of the expression of at least one marker selected from the group consisting of CD318, CD90, CD66 and CD13 and/or a transformed cell wherein BMI1 gene has been introduced into the human hepatic stem cell. Specific examples of the extracellular matrix and/or the growth factor include, but are not limited to, laminin, type I collagen, type IV collagen, fibronectin, metrigel, dexamethasone, DMSO, oncostatin M, insulin, HGF, EGF, TGFα, HB-EGF, VEGF and PDGF. The treatment with an extracellular matrix and/or a growth factor may be performed by culturing a human tissue stem cell with the phenotypes of CD318+CD90+CD66− in a medium containing the extracellular matrix molecule and/or the growth factor. Specific examples of the medium include, but are not limited to, a mixed medium of DMEM and F-12 Ham, William's medium E and RPMI1640 medium. Culture may be continued until cells reached 90% confluence in culture dishes. When cells reached 90% confluence, passage may be carried out as described below. Briefly, the culture medium is removed; the cells are treated with 0.05% trypsin-EDTA at room temperature for 5 min and gently detached from dishes by tapping; the suspended cells are washed with a culture medium containing 10% FBS and then replated in a culture medium.
Alternatively, the differentiation into a liver cell which expresses drug-metabolizing enzymes and/or transporters at the protein level may be induced by three-dimensional culture of a human hepatic stem cell soiled based on the presence or absence of the expression of at least one marker selected from the group consisting of CD318, CD90, CD66 and CD13 and/or a transformed cell wherein BMI1 gene has been introduced into the human hepatic stem cell. For three-dimensional culture of cells, it is preferable to use a three-dimensional culture system using a culture substratum for three-dimensional culture, collagen gel, or the like.
The present invention also provides a liver cell expressing drug-metabolizing enzymes and/or transporters at the protein level, which has been obtained by inducing differentiation of a human hepatic stem cell sorted based on the presence or absence of the expression of at least one marker selected from the group consisting of CD318, CD90, CD66 and CD13 and/or a transformed cell wherein BMI1 gene has been introduced into the human hepatic stem cell. Specific examples of drug-metabolizing enzymes include, but are not limited to, CYP3A4, CYP2C9, CYP2C19, CYP2D6, CYP2B6, CYP2E1 and CYP2A6. Specific examples of transporters include, but are not limited to, MRP2, MRP3, MDR1 and BCRP. For example, one or two or more transporters selected from the following may be expressed: ABC2, ABCA6, ABCA8, MDR1, MDR3, BSEP, MRP1, MRP2, MRP5, MRP6, ABCG8, NTCP, PEPT1, OATP-C, OATP8, OATP-B, OATP-F, OCT1, OAT2, SLC22A18, CNT1, ENT1 and MATE1. It is possible to evaluate the metabolism and/or transportation of drug candidate compounds using the liver cell of the present invention which expresses drug-metabolizing enzymes and/or transporters at the protein level.
Therefore, the present invention also provides a method of evaluating the metabolism and/or transportation of drug candidate compounds using the above-described liver cell expressing drug-metabolizing enzymes and/or transporters at the protein level. As one example, a drug candidate compound may be added to a cultured liver cell that expresses drug-metabolizing enzymes and/or transporters at the protein level and then examined for its metabolism and/or transportation. The metabolism and/or transportation of drug candidate compounds may be determined by such methods as mass spectrometry and HPLC analysis. The drug candidate compound may be any substance. For example, proteins, peptides, vitamins, hormones, polysaccharides, oligosaccharides, monosaccharides, low molecular weight compounds, nucleic acids (DNA, RNA, oligonucleotides, mononucleotides, etc.), lipids, natural compounds other than those listed above, synthetic compounds, plant extracts, fractionated products from plant extracts, and mixtures thereof may be enumerated.
Hereinbelow, the present invention will be described more specifically with reference to the following Example. However, the present invention is not limited to this Example.
The human fetal liver cells used in the present study were isolated by ACBRI (Applied Cell Biology Research Institute, a registered Washington non-profit research institution) in the US under the consent of the supplier and provided for free by Cell Systems in the US (Cat No. CS-ABI-3716). In Japan, the human fetal liver cells are supplied by Dainippon Pharmaceutical as Human Primary Fetal Hepatocytes (Cat No. CS-ABI-3716). This product was used in the present study. The results of infection tests (with HIV, HBV and HCV) and tests on microorganisms (fungi, bacteria and Mycoplasma) were negative. The present study has been deliberated and approved at the ethics committee of the university to which the present inventors belong.
The modifications as described below were made to an already established and reported low-density culture system for clonogenic fetal liver cells (Zheng Y W, Taniguchi H, et al. Transplant Prow 2000; 32:2372-2373; Suzuki A, Zheng Y W, et al. Hepatology 2000; 32:1230-1239).
The primary fetal liver cells, cells fractionated by flow cytometry or BMI1-transfected transformed cells were plated in DMEM nutrient mixture F-12 Ham (DMEM/F12 1:1 mixture, SIGMA) supplemented with 10% fetal bovine serum (FBS), human γ-insulin (1.0 μg/ml, Wako, Japan), nicotinamide (10 mM, SIGMA), dexamethasone (1×10−7M, SIGMA) and L-glutamine (2 mM, GIBCO BRL) in type IV collagen-coated dishes (Becton Dickinson Labware) and cultured for about two to three weeks or longer, with complete medium change performed every five days. Growth factors such as human recombinant HGF (50 ng/ml, SIGMA) and epidermal growth factor (EGF) (10 ng/ml, SIGMA) were added 24 hours after the plating.
When cells reached 90% confluence in culture dishes, passage was performed as described below. Briefly, the culture medium was removed; the cells were treated with 0.05% trypsin-EDTA at room temperature for 5 min and gently detached from dishes by tapping; the suspended cells were washed with a culture medium containing 10% FBS and then replated in a culture medium. The results of trypan blue staining revealed that the viability of dissociated cells was never lower than 90%. Depending on the experiment design, the plating density of cells was determined from single cell culture (a technique of culturing a single flow-cytometrically sorted cell in one well of a 96-well plate), low density culture at 100-500 cells/cm2 or high density culture at 1×103 cells/cm2.
Flow cytometric sorting and single cell-based assays were performed in this study. For assessing the clonogenic and proliferative capacities of flow cytometrically fractionated cells, hepatocyte clonal colony-forming units in culture (H-CFU-C) and the relative frequency of H-CFU-C formation in plated cells were determined after two- to three-week culture. H-CFU-C is defined as a unit capable of forming a colony containing 500 or more cells derived from a single cell capable of proliferation in vitro.
Suspended cells were incubated on ice with fluorochrome-conjugated monoclonal antibodies (mAbs) at optimized concentrations for 30 min in the dark. 2% FBS-supplemented PBS was used as a washing solution and an antibody diluent. When biotinylated primary antibody was used, secondary reaction was performed with streptavidin-labeled fluorescent antibody. All fluorochrome-conjugated mAbs were purchased from Becton Dickinson excepting those listed below: fluorescein isothiocyanate (FITC)-conjugated anti-human CD66 (hCD66FITC), allophycocyanin (APC)-conjugated hCD90, phycoerythrin (PE)-conjugated hCD318, hCD24FITC, hCD29FITC, hCD44PE, hCD49fPE, biotinylated hCD54 (eBioscience); hCD117APC, hCD138PE (Miltenyi Biotec), hCD140aPE and Streptavidin-labeled APC. Cell profiling analyses and sorting were performed on a high speed cell sorter, MoFlo (DakoCytomation).
PAS stain (periodic acid-Schiff stain): Periodic acid-Schiff stain was performed to determine the glycogen synthesis and storage in cultured cells.
In dual or triple immunocytochemical staining, cells were fixed with cold ethanol for 30 min and then blocked with 10% normal goat serum (NGS) for 60 min. Subsequently, a primary antibody was diluted with 1% NGS-supplemented PBS and reacted with the cells in a moist chamber at 4° C. overnight. A secondary antibody was diluted with 10% glycerol-containing PBS and reacted with the cells in a moist chamber at room temperature for 60 min. The cell nuclei were counter-stained with DAPI and mounted with an FA mounting fluid. (Images were captured with Zeiss AxioImager microscope.)
Primary antibodies used in innunocytochemical assays were mouse anti-human albumin mAb (SIGMA), mouse anti-human CK19 mAb (Pyogen), and rabbit anti-human CYP 3A4 (Chemicon), CYP 2D6 (Chmicon), CYP 2C9 (Daiichi Pure Chemicals; Tokyo). Secondary antibodies used in the assays were Alexa488-conjugated goat anti mouse IgG, Alexa555-conjugated goat anti mouse IgG, Alexa647-conjugated goat anti mouse IgG and Alexa488-conjugated goat anti-rabbit IgG (Invitrogen, Molecular Probes).
Total RNA from cells or cell colonies was extracted using Isogen reagent (Nippon Gene, Toyama, Japan). Before reverse transcription (RT), 150 ng of random primers and 1 μl of 10 mM dNTP mix were added to the total RNA solution. The reaction mixture was heated at 65° C. for 5 min and incubated on ice for 1 minute. Subsequently, 1× first-strand buffer, 0.5 mM dNTP mix, 5 mM DTT and 200 units of Super Script III (Invitrogen) were added to the reaction mixture, which was then incubated at 25° C. for 5 min, at 50° C. for 45 min and at 70° C. for 15 min to thereby synthesize cDNA from the total RNA. Semi-quantitative PCR was performed in 20 μl of reaction mixture (1×PCR buffer, Taq DNA polymerase) (Takara Shuzo Co., Tokyo, Japan). PCR was performed using hepatocyte-specific primers for the following: albumin [5′-tgttgattgcctttgacag-3′ (SEQ ID NO: 1) and 5′-tggagactggcacacttgag-3′(SEQ ID NO; 2)]; AFP [5′-agcttggtggtggatgaaac-3′ (SEQ ID NO: 3) and 5′-ccctcttcagcaaagcagac-3′ (SEQ ID NO: 4)]; G6P [5′-gtcaacacattacctccagg-3′ (SEQ ID NO: 5) and 5′-gagtagatgtgaccatcacg-3′ (SEQ ID NO; 6)]; CYP3A4 [5′-aacagcctgtgctggctatc-3′ (SEQ ID NO: 7) and 5′-gatcacatccatgctgtagg-3′ (SEQ ID NO: 8)]; CYP2C9 [5′-gcaggaaaacggatttgtgt-3′ (SEQ ID NO: 9) and 5′-caggccatctgacttcttc-3′ (SEQ ID NO; 10)]; CYP2C19 [5′-cttcaccctgtgatcccact-3′ (SEQ ID NO: 11) and 5′-aaagtcccgagggttgttg-3′ (SEQ ID NO: 12)]; CYP2D6 [5′-aggaggagtcgggattctg-3′ (SEQ ID NO; 13) and 5′-cttggccttctccatctctg-3′ (SEQ ID NO; 14)]; CYP1A2 [5′-cagaatgccctcaacacctt-3′ (SEQ ID NO: 15) and 5′-gctcctggactgttttctgc-3′(SEQ ID NO: 16)]; CYP2B6 [5′-aacctgcaggaaatcaatgc-3′ (SEQ ID NO: 17) and 5′-attttggctcggtcatgaag-3′ (SEQ ID NO: 18)]; CYP2E1 [5′-acccgagacaccattttcag-3′ (SEQ ID NO: 19) and 5′-agggtgtcctccacacactc-3′ (SEQ ID NO: 20)], for GAPDH [5′-ctctgetcctcctgttcgac-3′ (SEQ ID NO: 21) and 5′-ttgattttggagggatctcg-3′ (SEQ ID NO: 22)]; EGFP [5′-ctacggcgtgcagtgcttca-3′ (SEQ ID NO: 23) and 5′-cgctgccgtcctcgatgttg-3′ (SEQ ID NO: 24)]; BMI1 [5′-aatccccacctgatgtgtgt-3′ (SEQ ID NO: 25) and 5′-catttttgaaaagccctgga-3′ (SEQ ID NO: 26)]; TAT [5′-ttctggcagtggctgcac-3′ (SEQ ID NO: 27) and 5′-cccatctcggatctcattgc-3′ (SEQ ID NO: 28)], for GULU [5′-aaggcatcaagcaggtgtac-3′ (SEQ ID NO: 29) and 5′-gctggttgctcaccatgtcc-3′ (SEQ ID NO: 30)]; GGT [5′-acaaccatgtgtacaccagg-3′ (SEQ ID NO: 31) and 5′-ctggtgtgccagctcatacg-3′ (SEQ ID NO: 32)]; Desmin [5′-aagctgcaggaggagattca-3′ (SEQ ID NO; 33) and 5′-ggcagtgaggtctggcttag-3′ (SEQ ID NO: 34)]; CYP2A6 [5′-agaggaagagcaaggggaag-3′ (SEQ ID NO: 35) and 5′-ctgaactcctcagcctggtc-3′ (SEQ ID NO: 36)]; MRP2 [5′-tgcttcctggggataatcag-3′ (SEQ ID NO; 37) and 5′-cacggataactggcaaacct-3′ (SEQ ID NO: 38)]; MDR1 [5′-gctcctgactatgccaaagc-3′ (SEQ ID NO: 39) and 5′-tcttcacctccaggctcagt-3′ (SEQ ID NO: 40)]; MRP3 [5′-tgtgctaggtgatggacagg-3′ (SEQ ID NO: 41) and 5′-tgtcacctgcaccttctctg-3′ (SEQ ID NO: 42)]; BCRP [5′-ttttctgttcccttgccatc-3′ (SEQ ID NO: 43) and 5′-cctggccctctactctaccc-3′ (SEQ ID NO; 44)]; PROM1 [5′-tccaacagggctatcaatcc-3′ (SEQ ID NO: 45) and 5′-ccaaagacaaaggtaagaaccac-3′ (SEQ ID NO: 46)]; CD24 [5′-cccatcttctaaacccaatcc-3′ (SEQ ID NO: 47) and 5′-cattccacaatcccatcctt-3′ (SEQ ID NO: 48)]; CD44 [5′-tttacagcetcagcagagca-3′ (SEQ ID NO: 49) and 5′-cgatgctcagagctttctcc-3′ (SEQ ID NO: 50)]; ALCAM [5′-cgtctgctcttctgcctat-3′ (SEQ ID NO: 51) and 5′-tggttgcttgaacaccttga-3′ (SEQ ID NO: 52)]; and EPCAM [5′-tgatcctgactgcgatgaga-3′ (SEQ ID NO: 53) and 5′-gcacaacaattccagcaaca-3′ (SEQ ID NO: 54)]. PCR conditions were as follows: initial denaturation at 94° C. for 30 sec, annealing at 60° C. for 30 sec and extension at 72° C. for 30 sec. For GAPDH, annealing temperature was 57° C.; for EGFP and BMI1, annealing temperature was 64° C.; and for TAT, annealing temperature was 65° C. PCR products were electrophoresed in 1.5% agarose gel.
Taqman probes and primers for albumin (Hs00609411_m1), CYP3A4 (Hs01546612_m1), CYP2C9 (Hs00426397_m1), CYP2D6 (Hs02576167_m1) and 18S rRNA (4319413E) were obtained from TaqMan Gene Expression Assays (Applied Biosystems).
For preparing the retrovirus vector used in the present study, a retrovirus vector pGCDNsam IRES-EGFP (Nabekura T, Otsu M, et al. Mol Ther. 2006; 13(2):301-9) with which stable and long-term expression of the introduced gene can be expected and packaging cell strains (293GP and 293GPG cells) (provided by Prof. Makoto Ohtsu, Center for Stem Cell Biology and Regenerative Medicine, the Institute of Medical Science, the University of Tokyo) in which virus vector production can be induced by using a tetracycline-inducible system (TET-ON/OFF) were used (Burns J C, Friendmann T, et al. Proc. Natl. Acad. Sci. USA 1993, 90: 8033-7; Ory D S, Neugeboren B A, et al. Proc Natl Acad Sci USA. 1996, 93:11400-6).
The cDNA of BMI1 cloned from a human fetal liver was integrated into pGCDNsam IRES-EGFP vector at the multi-cloning site (NotI-BamHI) upstream of IRES domain. The resultant vector was introduced into the packaging cell (293GP cells) with calcium phosphate reagent (Promega). Subsequently, 293GPG cells were infected with the produced virus vector to thereby establish a stable expression strain under the condition of TET-ON.
These cells were cultured under the condition of TET-OFF. The resultant culture supernatant containing the produced virus vector was concentrated by centrifugation (6000×g, 4° C., 16 hr) and suspended in StemPro-34 Serum Free Medium (Invitrogen). The titer of the resultant virus vector was confirmed with Jurkat cells (RIKEN BRC) (7.9×106 infectious units/ml).
Culture of these packaging cell strains was performed in DMEM medium containing 10% FBS (Gibco), 2 mmol/L L-glutamine (Gibco), 2 μg/ml Puromycin (Sigma), 0.3 mg/ml G418 (Sigma) and 1× penicillin/streptomycin (Gibco) at 37° C. under 10% CO2. For culture dishes, those coated with poly-L-lysine were used.
Subsequently, for establishing a BMI1-transfected hepatic stem cell clone, the virus vector was introduced into human hepatic stem cells one week after their plating in the presence of protamin sulfate (10 μg/ml, Wako), followed by centrifugation (540×g, 32° C., 30 min) and incubation (37° C., 5% CO2, 1.5 hr). Seventy-two hours later, BMI1-transfected cells were enriched by flow cytometry (EGFP positive ratio: 99%).
Type IV collagen (Nitta Gelatin, Osaka) was coated on the surface of a micropattern cell culture film (PMMA/EH; provided by Kuraray). Human fetal liver cells or BMI1-transfected transformed cells were plated so that the number of cells per microcavity was five, and cultured (7.5×104 cells/well of a 24-well plate). Medium exchange was performed 24 hr after plating; thereafter, medium was changed once in one or two days. At the time of medium exchange, addition of EGF and HGF was also carried out. The medium was of the same composition as in two-dimensional culture.
As one of the most important indicators in identifying stem cells, the clonal colony-forming efficiency of the liver cells should be examined. The present inventors cultured human fetal liver cells at fetal week 14-18 at different plating densities (500, 400, 200 and 100 cells/cm2) using the low density culture method which is widely used for assessing clonal colony-forming efficiency. As a result, clonal colony formation was confirmed at plating densities of 200 cells/cm2 and 100 cells/cm2. Further, as shown in the inserted box, these colonies had a typical hepatocytic morphology.
In order to identify human primary liver cells in vitro, the present inventors carried out immunocytochemical assays with the hepatocytic lineage marker albumin, the cholangiocytic lineage marker cytokeratin 19 and the undifferentiated liver cell (hepatoblast) marker AFP. As a result, the existence of cells that co-express two cell lineage markers (i.e., have bi-potential differentiation capability) was confirmed. From
In addition to the clonal colony-forming efficiency described above, differentiation capability is another important indicator to assess the potential as stem cell. The inventors carried out PAS staining on primary fetal liver cells at day 7, day 21 and day 35 of culture. The results revealed that glycogen storage increases in proportion to the number of days of culture. From this fact, it was proved that primary fetal liver cells differentiate from undifferentiated liver cells to functional liver cells. The upper panels of
In addition to expression analyses at the protein level in liver cells, expression analyses at the RNA level were also performed in the present study. Gene expression analyses were performed on liver function markers (5 types indicated at the left: AFP, ALB, TAT, GLUL, GGT, G6P), cytochrome P450 (8 types indicated in the center: CYP3A4, CYP2D6, CYP2C9, CYP1A2, CYP2C19, CYP2A6, CYP2B6, CYP2E1) and transporters (4 types indicated at the right: MRP2, MRP3, MDR1, BCRP). The results revealed that almost all of these genes expressed in adult liver tissue are also expressed in the primary fetal liver cells induced for differentiation. It was also confirmed that their expression levels increase in proportion to the number of days of culture for induction of differentiation. As a positive control, human adult liver tissue was used.
From these results, the present inventors judged that the primary fetal liver cells obtained from ACBRI are suitable for isolation of stem cells at higher enrichment, and decided to use those cells in the present study.
Profiling of the surface antigens of human primary fetal liver cells was performed using flow cytometry and fluorochrome-conjugated monoclonal antibodies.
As shown in the upper row of
Given the expressions of surface antigens that provide these extremely positive or negative cell ratios, it is operationally difficult to carry out cell separation using such expressions as an indicator, so the present inventors decided that to isolate and identify hepatic stem cells in the present study, the expressions of surface antigens that were verified to show moderately positive cell ratios in profiling should be used as an indicator for separation.
This Figure shows a flow chart of cell sorting by flow cytometry.
First, cells were passed through the gate of FSC (Forward Scatter) and SSC (Side Scatter) to remove debris and fragments. Then, PI negative cell (viable cell) fraction was sorted out. This fraction was further fractionated using the expressions of CD66, CD90 and CD318 as an indicator. The inventors performed assessment of clonal colony-forming efficiency of a single cell for each of the positive and negative cell fractions corresponding to the expression of a single marker, as well as cell fractions No. 1 to No. 4 shown in the right panel. As a result, the present inventors found a cell population with high proliferative activity in CD318+CD90+CD66− cell fraction. (Quantitative results are shown in
Cell sorting was performed using various monoclonal antibodies in varied combinations. Finally, a cell population with high clonal colony-forming efficiency was found in CD318+CD90+CD66− cell fraction.
In order to observe the clonal colony formation and pluripotency of hepatic stem cells, single cell sorting was performed in 96-well plates. At day 18 of culture, a clonal colony was formed as shown in
For each of the cell fractions indicated in
A single hepatic stem cell isolated by flow cytometry was monitored from day 1 through day 20 of culture. Hepatic stem cells showing vigorous proliferative activity in vitro are capable of forming a gigantic colony from a single cell.
In order to assess the proliferative activity of hepatic stem cells in vitro, cell culture from a single hepatic stem cell has now been continued for 8 months or longer. This cell still retains a typical morphology of liver cells and is showing stable proliferative activity.
Therefore, it can be concluded that CD318+CD90+CD66− cells showing high proliferative capacity in vitro have properties of stem cells.
One of the human hepatic stem cell clones with the phenotypes of CD318+CD90+CD66− was designated LSC-E2 and deposited at the International Patent Organism Depository, National Institute of Advanced Industrial Science and Technology (accession number: FERM BP-11108; date of accession: Apr. 3, 2008).
Gene expression analyses were performed in order to prove that the isolated hepatic stem cells have not only proliferative capacity but also pluripotency. As shown in
A single hepatic stem cell was cultured in a 96-well plate, followed by immunocytochemical assays on albumin and cytokeratin 19.
PAS staining images of hepatic stem cells cultured for as long as 80 days are shown. The right panel shows a bright field image and the left panel a phase contrast image. Since PAS stain positive cell means that it has glycogen storage capacity, hepatic stem cells are believed to have differentiated as a result of long-term culture.
The present inventors proved the differentiation capability of hepatic stem cell-derived clonal colonies after long-term culture for three months. The hepatic stem cell-derived clonal colonies expressed such markers as cytochrome P450 1A2, 2D6 and 3A4 that suggest differentiation capability like albumin. Since cells that are positive for both CYP 3A4 and albumin were found in the colonies, it is believed that isolated hepatic stem cells have differentiation capability and that functional liver cells can be maintained in the culture system used in the present study.
Therefore, it can be concluded that the hepatic stem cells isolated in the present study have pluripotency and can be induced to differentiate into functional liver cells through long-term culture.
Introduction of BMI1 gene into hepatic stem cells was confirmed with GFP fluorescence used as an indicator. No morphological difference was observed between BMI1 overexpressing cells, mock and wild-type (WT) cells. However, BMI1 overexpressing cell-derived colonies were larger than control cell-derived colonies.
When the cell numbers in BMI1 overexpressing cell-derived clonal colonies were compared to the cell numbers in mock- or WT-derived colonies, about two-fold increase was observed on average. Despite the introduction of BMI1 gene into hepatic stem cells, no change was observed between those stem cells and WT as regards the number of H-CFU-C. On the other hand, the number of H-CFU-C in those stem cells was three times as large as that number in mock. These results made it clear that introduction of BMI1 gene into hepatic stem cells enhances their proliferative capability but does not affect the frequency (H-CFU-C) of hepatic stem cells.
Since it is impossible to assess the properties of BMI1 overexpressing cells by phenotype alone, their differentiation capability was analyzed using the expression of hepatocytic lineage markers and hepatic function markers as an indicator.
Immunocytochemical assays confirmed the expression of albumin and CYP3A4, 2C9 and 2D6 in BMI1 overexpressing cells. Those cells which were positive for both albumin and cytochrome P450 produced very vivid stain images.
Expression of albumin, AFP, G6P and cytochrome P450 genes was confirmed by RT-PCR and Taqman real time PCR. From the results of RT-PCR shown in
In summary, compared to wild-type stem cells, BMI1 overexpressing stem cells possess higher clonal expansion capability and strongly express liver function markers such as cytochrome P450.
Bioreactor systems are gradually attracting attention as a three-dimensional culture system and are capable of culturing cells while maintaining the in vivo cell functions which were frequently lost in conventional two-dimensional culture. It is believed that this advantage is achieved because cell-to-cell interactions are enhanced in three-dimensional culture systems. The present inventors performed experiments using a three-dimensional culture system, or a simulated in vivo environment provided by Kuraray [a micropatterned film comprising numerous microcavities (L×W×D=100 μm×100 μm×50 μm)].
The present inventors cultured cells at a plating density of 5 cells/cavity and confirmed cell adhesion and proliferation. Thus, it was demonstrated that smooth culture is possible with the three-dimensional culture system, Cells initially adhered to the bottom of the film, and with the passage of time, they gradually extended to other microcavities and formed a cellular aggregate at the center of each microcavity.
Human hepatic stem cell fractions were sorted by flow cytometry, followed by overexpression of BMI1 with a retrovirus vector (hereinafter, the thus prepared cell is called “BMI1-transfected transformed cell”). Since the expression of BMI1 can be confirmed using the expression of a reporter gene FOP as an indicator, BMI1-transfected transformed cell emits green fluorescence as shown in
Expressions of hepatocytic lineage markers and CYP450 genes were observed. Then, quantitative analyses of gene expressions were performed for each of the culture periods in two-dimensional and three-dimensional culture systems. The results revealed that the expression level of albumin gene in three-dimensional culture system decreased with the passage of time, but on the average, it exceeded the expression level of albumin gene in two-dimensional culture system. While the expression level of CYP3A4 gene decreased greatly in two-dimensional culture system with the passage of time, it retained a stable level in three-dimensional culture system and, on the average, exceeded the corresponding level in two-dimensional culture system. Further, the expression levels of CYP2D6 and CYP2C9 genes were higher in three-dimensional culture system than in two-dimensional culture system for both culture periods. As far as CYP2D6 gene is concerned, the expression level in three-dimensional culture system far exceeded the expression level in two-dimensional culture system. The expression of CYP2C9 gene achieved a high level by two-week culture in three-dimensional culture system. Although the expression level decreased with the passage of time, the expression still maintained a high level compared to the corresponding expression level in two-dimensional culture system. Therefore, it can be concluded that three-dimensional culture system contributes not only to the differentiation of human hepatic stem cells into liver cells that express drug-metabolizing enzymes, etc. but also to the maintenance of the functions of differentiated stem cells.
The numerical values given in
Gene expression analysis was performed on BMI1-transfected transformed cell cultured three-dimensionally, human primary fetal liver cells, adult-derived human liver cells and human liver tissue using real time PCR. As a result, expression of drug-metabolizing enzymes equivalent to the expression in human primary fetal liver cells was confirmed in BMI1-transfected transformed cell cultured three-dimensionally. The expression levels of drug-metabolizing enzymes in BMI1-transfected transformed cell cultured three-dimensionally were confirmed to be close to the corresponding expression levels in human liver tissue and adult-derived human liver cells. This shows the efficacy of drug evaluation tests using BMI1-transfected transformed cell cultured three-dimensionally.
The most important point in HCV researches is to develop a highly reproducible and efficient culture system. Recently, several candidates for HCV receptors have been reported. For example, CD81 tetraspanin, scavenger receptor BI (SR-BI) and low-density lipoprotein (LDL) receptors may be enumerated. DNA microarray analyses of human primary fetal liver cells and isolated human hepatic stem cells using Affymetrix GeneChip Human Genome U133 Plus 2.0 Array and GeneSpring GX9.0 analysis software revealed that the expression level of HCV receptor CD81 in hepatic stem cells was significantly increased (Table 1). Further, flow cytometric analyses detected the expression of HCV receptors CD81 and LDLR (
Analyses of Lipid Metabolism- and Glucogenesis-Associated Genes in Human Liver Cells Induced to Differentiate from Hepatic Stem Cells (
Gene expression analyses were performed by semi-quantitative PCR on BMI1-transfected transformed cells cultured three-dimensionally, co-culture of this transformed cell and vascular endothelial cells, as well as hepatic stem cells, primary fetal liver cells, and human liver tissue as a control. Table 2 shows the primer sequences used. As a result, expression of lipid metabolism- and glucogenesis-associated genes equivalent to the expression in human liver tissue was confirmed in BMI1-transfected transformed cell cultured three-dimensionally (
1) BMI1-3D: BMI1-transfected transformed cell cultured in three-dimensional culture system.
2) BMI1-3D co-culture: Culture obtained by co-culturing the above-described cell and human vascular endothelial cells in three-dimensional culture system.
3) Primary fetal liver cells: Primary human fetal liver cells.
4) Hepatic stem cells: Hepatic stem cells isolated from primary fetal liver cells.
5) Fetal Liver: Human fetal liver total RNA from Clontech, a Takara Bio Company.
6) Adult liver: Human liver total RNA from Clontech, a Takara Bio Company.
1) upstream stimulator factors 1 (USF1)
2) sterol response element binding protein (SREBP-1)
3) acetoacetyl-CoA
4) Isopentenyl pyrophosphate 1 (IPP1)
4) HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A)
5) STATS (signal transducer and activator of transcription 3)
1) pyruvate carboxylase (PC)
2) malate dehydrogenase 2 (MDI-12)
3) phosphoenolpyruvate carboxykinase (PEPCK)
CD13 is one of mesenchymal stem cell markers. DNA microarray analysis using Affymetrix GeneChip Human Genome U133 Plus 2.0 Array and GeneSpring GX9.0 analysis software revealed that the expression level of CD13 in isolated hepatic stem cells was 2.7 times higher than the corresponding expression level in primary fetal liver cells (4001.1/1457.7).
All publications, patents and patent applications cited herein are incorporated herein by reference in their entirety.
The human hepatic stein cell isolated according to the present invention is capable of contributing greatly to regenerative medicine such as artificial liver or cell transplantation. Human liver cells induced to differentiate from the isolated human hepatic stem cell may be used in drug development researches such as analysis of in vitro drug-metabolizing ability. In particular, BMI1-transfected human hepatic stem cells may be handled as a cell strain in cell operations and human liver cells induced to differentiate from them have extremely high utility in drug development industry. Further, these cells may be used as human model cells in experiments on HCV infection and/or inhibition of HCV replication, glucose metabolism experiments, lipid metabolism experiments, and so forth.
SEQ ID NOS: 1 and 2 show the sequences of liver cell specific primers for albumin.
SEQ ID NOS: 3 and 4 show the sequences of liver cell specific primers for AFP.,
SEQ ID NOS: 5 and 6 show the sequences of liver cell specific primers for GP6,
SEQ ID NOS: 7 and 8 show the sequences of liver cell specific primers for CYP3A4,
SEQ ID NOS: 9 and 10 show the sequences of liver cell specific primers for CYP2C9.
SEQ ID NOS: 11 and 12 show the sequences of liver cell specific primers for CYP2C19.
SEQ ID NOS: 13 and 14 show the sequences of liver cell specific primers for CYP2D6.
SEQ ID NOS: 15 and 16 show the sequences of liver cell specific primers for CYP1A2.
SEQ ID NOS: 17 and 18 show the sequences of liver cell specific primers for CYP2B6.
SEQ ID NOS: 19 and 20 show the sequences of liver cell specific primers for CYP2E1.
SEQ ID NOS: 21 and 22 show the sequences of liver cell specific primers for GAPDH.
SEQ ID NOS: 23 and 24 show the sequences of liver cell specific primers for EGFP.
SEQ ID NOS: 25 and 26 show the sequences of liver cell specific primers for BMI1
SEQ ID NOS: 27 and 28 show the sequences of liver cell specific primers for TAT.
SEQ ID NOS: 29 and 30 show the sequences of liver cell specific primers for GULU.
SEQ ID NOS: 31 and 32 show the sequences of liver cell specific primers for GGT.
SEQ ID NOS: 33 and 34 show the sequences of specific primers for Desmin
SEQ ID NOS: 35 and 36 show the sequences of liver cell specific primers for CYP2A6.
SEQ ID NOS: 37 and 38 show the sequences of liver cell specific primers for MRP2.
SEQ ID NOS: 39 and 40 show the sequences of liver cell specific primers for MDR1.
SEQ ID NOS: 41 and 42 show the sequences of liver cell specific primers for MRP3.
SEQ ID NOS: 43 and 44 show the sequences of liver cell specific primers for BCRP.
SEQ ID NOS: 45 and 46 show the sequences of specific primers for PROM1.
SEQ ID NOS: 47 and 48 show the sequences of specific primers for CD24.
SEQ ID NOS: 49 and 50 show the sequences of specific primers for CD44.
SEQ ID NOS: 51 and 52 show the sequences of specific primers for ALCAM.
SEQ ID NOS: 53 and 54 show the sequences of specific primers for EPCAM.
SEQ ID NOS: 55 and 56 show the nucleotide sequence of human BMI1 used in the present study (CDS nucleotide sequence (981 bp)) and the amino acid sequence thereof (326 amino acids), respectively (GenBank accession number: NM—005180.5).
SEQ ID NOS: 57 and 58 show the sequences of specific primers for PEPCK.
SEQ ID NOS: 59 and 60 show the sequences of specific primers for PC.
SEQ ID NOS: 61 and 62 show the sequences of specific primers for MDH2.
SEQ ID NOS: 63 and 64 show the sequences of specific primers for STAT3.
SEQ ID NOS: 65 and 66 show the sequences of specific primers for USF1.
SEQ ID NOS: 67 and 68 show the sequences of specific primers for SREBF1.
SEQ ID NOS: 69 and 70 show the sequences of specific primers for Acetoacetyl-CoA.
SEQ ID NOS: 71 and 72 show the sequences of specific primers for IPP1.
SEQ ID NOS: 73 and 74 show the sequences of specific primers for HMG-CoA.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2008-127755 2008 | May 2008 | JP | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/JP2009/058932 | 5/13/2009 | WO | 00 | 11/11/2010 |
